anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypersensitivity Reactions: Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir sulfate, a component of TRIZIVIR. Hypersensitivity to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: (1) fever, (2) rash, (3) gastrointestinal (including nausea, vomiting, diarrhea, or abdominal pain), (4) constitutional (including generalized malaise, fatigue, or achiness), and (5) respiratory (including dyspnea, cough, or pharyngitis). Discontinue TRIZIVIR as soon as a hypersensitivity reaction is suspected.

Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.

Regardless of HLA-B*5701 status, permanently discontinue TRIZIVIR if hypersensitivity cannot be ruled out, even when other diagnoses are possible.

Following a hypersensitivity reaction to abacavir, NEVER restart TRIZIVIR or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.

Reintroduction of TRIZIVIR or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of hypersensitivity to abacavir therapy, can result in serious or fatal hypersensitivity reactions. Such reactions can occur within hours [see Warnings and Precautions (5.1)].

Hematologic Toxicity: Zidovudine, a component of TRIZIVIR, has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV-1) disease [see Warnings and Precautions (5.2)].

Myopathy: Prolonged use of zidovudine has been associated with symptomatic myopathy [see Warnings and Precautions (5.3)].

Lactic Acidosis and Severe Hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir, lamivudine, zidovudine, and other antiretrovirals [see Warnings and Precautions (5.4)].

Exacerbations of Hepatitis B: Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of TRIZIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue TRIZIVIR and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.5)].
1409733 Tri-iodinated-N-methyl-dicarboxylic acid anilides SCHERING AG 7 Aug 1972 [17 Aug 1971] 36734/72 Heading C2C [Also in Division A5] Compounds I in which R 1 is hydrogen, halogen, carboxyl, acylamino, N-alkyl-N-acylamino, diacylamino, N-acylaminomethyl, a group of Formula III (in which A is a C 2-3 alkylene group optionally interrupted by an oxygen atom) or a group R 3 R 4 N-CO- (in which R 3 and R 4 are hydrogen, C 1-4 alkyl or hydroxy C 1-4 alkyl or NR 3 R 4 represents a heterocyclic group which may contain a further heteroatom), R 2 is halogen, hydroxyl, C 1-4 alkoxy, hydroxy C 1-4 alkoxy or C 1-4 alkoxy, C 1-4 alkoxy and X is a linear or branched saturated hydrocarbon group of 2-14 C atoms interrupted by one or more atoms selected from oxygen and sulphur, and salts of those compounds in which R 2 is hydroxyl are prepared by reaction of a compound II in which R 2 is halogen, hydroxyl alkoxy, alkoxy alkoxy with Hal-CO-X-CO-Hal (III) in which Hal is chlorine or bromine and if desired hydrolysing any resulting compound in which R 2 is halogen to form one in which R 2 is hydroxyl or converting the acid chloride with an appropriate alcohol into a compound I in which R 2 is alkoxy, hydroxyalkoxy or alkoxy alkoxy or esterifying a compound in which R 2 is hydroxyl. Sulphur atoms in group X may be present in an oxidized state. Compounds I are novel except those in which R 1 is acylamino, N-alkylacylamino or diacylamino and X is a C 2-14 hydrocarbon chain interrupted only by sulphur atoms. The acid halide III is derived from glycollic acid, thioglycollic acid, 3,6,9 - trioxaundecane - 1,11 - dicarboxylic acid or 4,7,10,13 - tetraoxa - hexadecane - 1,16- dicarboxylic acid. R 1 is hydrogen, chloro, carboxy, acetylaminomethyl, N-methylacetylamino, pyrrolidino - carbonyl or 2-oxopyrrolidino. Compounds I are X-ray contrast agents. Reference has been directed by the Comptroller to Specification 1,164,526.
[GB1409733A]
The invention relates to a novel clathrate complex (inclusion compound) of β-cyclodextrin and 5-hydroxy-4-aminomethyl-1-cyclohexyl (or cycloheptyl)-3-alkoxycarbonyl indole derivative, which has a molar ratio of 1:1 to 1:5. The clathrate complex may be in the form of nanoparticles of a size of less than 100 nm. Preferred are clathrate complexes, wherein 5-hydroxy-4-aminomethyl-1-cyclohexyl (or cycloheptyl)-3-alkoxycarbonyl indole derivative is 1- cyclohexyl-4-aminomethyl-5-hydroxy-2-methyl-1H-indole-3-carboxylic acid ethyl ester. Novel clathrate complexes exhibit an anti-viral effect and are highly active against influenza viruses. The invention also relates to a pharmaceutical composition and a drug based on the clathrate complexes. Furthermore, the invention relates to liquid-phase and solid-phase synthesis of the clathrate complexes.
Each cavity will be irradiated in contact mode with continuous wave of radiation. The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. The fiber optic will be disinfected for each use by 70% ethyl alcohol and inserted inside the cavity to 1mm with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. This procedure improves the distribution of the laser light inside the cavity and to avoid excessive heat generation in the internal cavity surface. Irradiation time will be 15 seconds and repeated 5 times with 15 second intervals with contact, according to manufacture instructions. During this study the output power will be adjusted at 1.5W.
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
Tobacco use is the leading preventable cause of death in the United States. Recent research on the effects of nicotine on the brain and behavior presents an opportunity to advance medication development. Neurotransmission at NMDA receptors in the brain is associated with learning and memory and has been linked to many of nicotine's effects on humans. It is possible that altering NMDA neurotransmission may be helpful in treating nicotine addiction. The goal of this study is to evaluate the effects of memantine, an NMDA receptor antagonist, using the laboratory model of smoking relapse in nicotine dependent volunteers. The effects of memantine used in combination with bupropion, a medication currently used to facilitate smoking cessation, will be compared to a placebo.

This double-blind study will consist of three phases (placebo, bupropion, and memantine). Each phase will include 10 days of outpatient medication maintenance, followed by 5 days of inpatient testing. During the outpatient phase, study visits will occur every 2 to 3 days. During the first portion of inpatient stay, participants will not be permitted to smoke. During the second portion of inpatient stay, smoking reinstatement will be modeled, as participant will have opportunity to smoke. A variety of behavioral, subjective, physiological, and performance measures will be assessed throughout the study.
It is planned to single-blind, randomized controlled study with before-after measurements. Considering the acute effects of stretching exercise for ankle dorsiflexion in older women, the effect size was calculated as 1.02. According to this effect size, it was planned to recruit 26 people to each group with 95% confidence level and 95% power, and 78 people in total would participate in the study. Ethics committee approval of the study was received from Dokuz Eylul University Non-Interventional Research Ethics Committee (with the decision number 2017/17-39 in the meeting dated 22.06.2017). The study was conducted under the Declaration of Helsinki standards. The participants were informed about the study by the physiotherapist and all the participants provided written informed consent to participate in the study. The study included healthy and voluntary older adults aged 65 and over who were able to walk without using an assistive device, independent in their daily life activities, and scored 23 and above according to the mini-mental state test in the study. The exclusion criteria of the study were the presence of a neurological, orthopedic or cardiovascular disease affecting the lower extremity, pain or limitation of movement in the ankle joint, skin diseases, history of falling in the last 1 year, any problem that may prevent lying prone and participation in a regular exercise program. Individuals meeting the inclusion criteria were randomly assigned to one of two different groups with the help of the Random Numbers Table. The study was terminated when the target number of participants (n=78) was reached. Static stretching was applied to the first group (n=26), PNF stretching to the second group (n=26), and roller massage to the third group (n=26). Individuals meeting the inclusion criteria were randomly assigned to one of two different groups with the help of the Random Numbers Table. The study was terminated when the target number of participants (n=78) was reached. Static stretching was applied to the first group (n=26), PNF stretching to the second group (n=26), and roller massage to the third group (n=26). (Figure 1) After the stretching method to be applied was determined randomly, the participants were asked to walk for 5 minutes in a 50-meter corridor. After warming up with this light-paced walking, applied one of the three methods. Immediately after the application, 10 minutes and 20 minutes after application, the range of motion of the ankle joint was measured in the weight-bearing lunge position.
The potential of extracellular vesicles (EVs) isolated from mesenchymal stromal cells in guiding macrophages toward anti-inflammatory immunophenotypes, has been reported in several studies. In our study, we provided experimental evidence of a distinctive effect played by Wharton Jelly mesenchymal stromal cell-derived EVs (WJ-EVs) on human macrophages. We particularly analyzed their anti-inflammatory effects on macrophages by evaluating their interactions with stellate cells, and their protective role in liver fibrosis. A three-step gradient method was used to isolate monocytes from umbilical cord blood (UCB). Two subpopulations of WJ-EVs were isolated by high-speed (20,000 g) and differential ultracentrifugation (110,000 g). Further to their characterization, they were designated as EV20K and EV110K and incubated at different concentrations with UCB-derived monocytes for 7 days. Their anti-fibrotic effect was assessed by studying the differentiation and functional levels of generated macrophages and their potential to modulate the survival and activity of LX2 stellate cells. The EV20K triggers the polarization of UCB-derived monocytes towards a peculiar M2-like functional phenotype more effectively than the M-CSF positive control. The EV20K treated macrophages were characterized by a higher expression of scavenger receptors, increased phagocytic capacity and production level of interleukin-10 and transforming growth factor-β. Conditioned medium from those polarized macrophages attenuated the proliferation, contractility and activation of LX2 stellate cells. Our data show that EV20K derived from WJ-MSCs induces activated macrophages to suppress immune responses and potentially play a protective role in the pathogenesis of liver fibrosis by directly inhibiting HSC's activation.
BACKGROUND: Keeping the health workforce and the public informed about the latest evolving health information during a health emergency is critical to preventing, detecting and responding to infectious disease outbreaks or other health emergencies. Having a well-informed, ready, willing, and skilled workforce and an informed public can help save lives, reduce diseases and suffering, and minimize socio-economic loss in affected communities and countries. Providing "just in time" support and opportunities for learning in health emergencies is much needed for capacity building. In this paper, 'learning intervention' refers to the provision of ad-hoc, focused, or personalized training sessions with the goal of preparing the health workers for emergencies or filling specific knowledge or skill gaps. We refer to 'training methods' as instructional design strategies used to teach someone the necessary knowledge and skills to perform a task.
METHODS: We conducted a scoping review to map and better understand what learning interventions and training methods have been used in different types of health emergencies and by whom. Studies were identified using six databases (Pubmed/Medline, Embase, Hinari, WorldCat, CABI and Web of Science) and by consulting with experts. Characteristics of studies were mapped and displayed and major topic areas were identified.
RESULTS: Of the 319 records that were included, contexts most frequently covered were COVID-19, disasters in general, Ebola and wars. Four prominent topic areas were identified: 1) Knowledge acquisition, 2) Emergency plans, 3) Impact of the learning intervention, and 4) Training methods. Much of the evidence was based on observational methods with few trials, which likely reflects the unique context of each health emergency. Evolution of methods was apparent, particularly in virtual learning. Learning during health emergencies appeared to improve knowledge, general management of the situation, quality of life of both trainers and affected population, satisfaction and clinical outcomes.
CONCLUSION: This is the first scoping review to map the evidence, which serves as a first step in developing urgently needed global guidance to further improve the quality and reach of learning interventions and training methods in this context.
PURPOSE:To prepare a dietary fiber material which functions very well as an absorbent member by acetylating a porous composite obtd. by foaming a composite consisting of a water-sol. dietary fiber and chitosan. CONSTITUTION:A porous composite obtd. by foaming a composite consisting of a water-sol. dietary fiber and chitosan and having a structure wherein chitosan is combined with or attached to the fiber chemically or physically is acetylated to give a stable porous composite wherein chitosan and the fiber have been fixed. The fiber is a water-sol. hardly digestable component mainly comprising a polysaccharide, examples having a vegetable-derived polysaccharide, a seaweed-derived polysaccharide, a microorganism-derived polysaccharide, and a chemically modified polysaccharide. The obtd. stable porous composite is excellent in water resistance and water retention and can be widely used as a water-retentive structure in medical, hygienic, and cosmetic applications.
Beginning 4 weeks after completion of last course of consolidation chemotherapy, patients receive autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes IV over 1-4 hours on day 0 and again after a minimum of 3 weeks. Beginning 6 hours after the second infusion of T cells, patients also receive aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity. Patients who have clinically benefitted from T cell therapy may receive additional infusions of T cells and aldesleukin at the discretion of the PI and the attending physician.
A therapeutic dosage form includes a pharmaceutically active ingredient, a crosslinked polyacid, and a linear polyacids. The crosslinked polyacid is insoluble in water, and the linear polyacid is soluble in water. An example of a crosslinked polyacids is sodium carboxymethylcellulose. The linear polyacid possesses sufficient binding sites to form a stable complex with the pharmaceutically active ingredient. An example of a linear polyacid is polymethacrylic acid. The ingredients are formed into a tablet or capsule, either admixed, in layers, or separated by a coating. Abuse is deterred in that crushing causes the active ingredient to be bound and not abusable, and placing the dosage in solution causes a strong complex to be formed between the polyacid and the active ingredient, including a solution with ethanol. Other therapeutic dosage forms for reducing the incidence of tampering and abuse of pharmaceutical products and alcohol, and specifically preventing the isolation and concentration of drug constituents for misuse, and preventing excessive intake are also disclosed.
BACKGROUND: Idiopathic short stature (ISS) is characterized by short stature with unknown causes. Recent studies showed different gut microbiota flora and reduced fecal short-chain fatty acids in ISS children. However, the roles of the microbiome and metabolites in the pathogenesis of ISS remains largely unknown.
METHODS: We recruited 51 Chinese subjects, comprising 26 ISS children and 25 normal-height control individuals. Untargeted metabolomics was performed to explore the fecal metabolic profiles between groups. A shotgun metagenomic sequencing approach was used to investigate the microbiome at the strains level. Mediation analyses were done to reveal correlations between the height standard deviation (SD) value, the gut microbiome and metabolites.
RESULTS: We detected marked differences in the composition of fecal metabolites in the ISS group, particularly a significant increase in erucic acid and a decrease in spermidine, adenosine and L-5-Hydroxytryptophan, when compared to those of controls. We further identified specific groups of bacterial strains to be associated with the different metabolic profile. Through mediation analysis, 50 linkages were established. KEGG pathway analysis of microbiota and metabolites indicated nutritional disturbances. 13 selected features were able to accurately distinguish the ISS children from the controls (AUC = 0.933 [95%CI, 79.9-100%]) by receiver operating characteristic (ROC) analysis.
CONCLUSION: Our study suggests that the microbiome and the microbial-derived metabolites play certain roles in children's growth. These findings provide a new research direction for better understanding the mechanism(s) underlying ISS.
The dose of LUNESTA should be individualized. The recommended starting dose for LUNESTA for most non-elderly adults is 2 mg immediately before bedtime. Dosing can be initiated at or raised to 3 mg if clinically indicated, since 3 mg is more effective for sleep maintenance (see PRECAUTIONS). 

The recommended starting dose of LUNESTA for elderly patients whose primary complaint is difficulty falling asleep is 1 mg immediately before bedtime. In these patients, the dose may be increased to 2 mg if clinically indicated. For elderly patients whose primary complaint is difficulty staying asleep, the recommended dose is 2 mg immediately before bedtime (see PRECAUTIONS). 

Taking LUNESTA with or immediately after a heavy, high-fat meal results in slower absorption and would be expected to reduce the effect of LUNESTA on sleep latency (see Pharmacokinetics under CLINICAL PHARMACOLOGY).
In the experimental group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with subarachnoid hemorrhage were included in the stratified random method. Use Magnesium-Rich Artificial Cerebrospinal Fluid(MACSF) in the CSF replacement, and the remaining treatments should strictly follow the guidelines as same as the control group. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10\^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
Male or female, aged between 18 and 65 years. Inclusion: 1) no history of whiplash trauma, no pain with a mean pain intensity of more than 2/10 on the visual analogue scale for \> 8 consecutive days in the preceding year in the neck-shoulder-arm region 2) painfree at the day of testing 3) native dutch speaker and 4) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments.
1397592 Making tubes; drawing; shearing KABELUND METALLWERKE GUTEHOFFNUNGSHUTTE AG 4 Aug 1972 [16 Aug 1971] 36578/72 Headings B3A B3P and B3W Strip, e.g. aluminium strip of less than 0À3 mm. thickness, is formed into a tube, from which edge portions of the strip project radially to form a longitudinal rib, by an outer former 1 with a frusto-conical bore and a complementary mandrel 2, the edge portions are trimmed to the same height to form cut surfaces which are then welded or soldered. The strip is fed to the forming tools under tension via deflecting rollers (10), (7), Fig. 3 (not shown), on a rockable frame, the roller (7) having collars (8), (9) adjustable to guide different widths of strip. The tube is located during trimmming in a guide 5 with the strip edge portions projecting through a slit 5A. Downstream of the shear, the trimmed edge portions are pressed together by an adjustable roller device for the welding or soldering operation (not shown).
This study is a multi-center, prospective, open-label, randomized, crossover study that is designed to gather clinical information on subjects' experiences with the use of the new feature of the RestoreSensor implantable neurostimulator. Current spinal cord stimulators for chronic intractable pain stimulate targeted nerves along the spine using electrical impulses. The stimulation interferes with the transmission of pain signals to the brain replacing painful sensations with a tingling sensation called paresthesia. Variation in the intensity of neurostimulation with body position is a challenge for some patients implanted with conventional spinal cord stimulation systems because positional changes may result in overstimulation or understimulation. Patients need to manually adjust their stimulation using the patient programmer to maintain their comfort level during position changes. The AdaptiveStim feature of the RestoreSensor neurostimulator was developed to address this challenge by improving pain relief and/or convenience relative to manual programming adjustments.
Installation of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.